1,208.12
price up icon7.13%   80.43
after-market After Hours: 1210.00 1.88 +0.16%
loading
Lilly Eli Co stock is traded at $1,208.12, with a volume of 7.70M. It is up +7.13% in the last 24 hours and up +13.47% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,127.69
Open:
$1128.8
24h Volume:
7.70M
Relative Volume:
2.43
Market Cap:
$1.08T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
43.49
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+9.97%
1M Performance:
+13.47%
6M Performance:
+12.10%
1Y Performance:
+51.94%
1-Day Range:
Value
$1,128.00
$1,215.76
1-Week Range:
Value
$1,079.22
$1,215.76
52-Week Range:
Value
$623.78
$1,215.76

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2026-08-06
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LLY icon
LLY
Lilly Eli Co
1,208.12 1.01T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
254.66 589.48B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
253.35 429.58B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
128.66 309.84B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
155.41 295.98B 54.66B 13.58B 16.05B 7.0171

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Downgrade HSBC Securities Hold → Reduce
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
02:55 AM

ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares - Stock Titan

02:55 AM
pulisher
01:56 AM

Form 144 ELI LILLY AND COMPANY For: 26 June By Investing.com - Investing.com Canada

01:56 AM
pulisher
01:07 AM

Eli Lilly (LLY) Hits All-Time High Amid Healthcare Sector Rally - GuruFocus

01:07 AM
pulisher
11:35 AM

The Investment Case for Eli Lilly and Co (LLY): How Financial Gr - GuruFocus

11:35 AM
pulisher
11:05 AM

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

11:05 AM
pulisher
11:05 AM

Eli Lilly (LLY) Gains EMA Support for Cancer and Diabetes Treatm - GuruFocus

11:05 AM
pulisher
10:31 AM

Why is Eli Lilly stock surging today? By Investing.com - Investing.com Canada

10:31 AM
pulisher
10:30 AM

Why is Eli Lilly stock surging today? - Investing.com

10:30 AM
pulisher
10:30 AM

Market movers: Triller Group, Eli Lilly, Onsemi… - Proactive financial news

10:30 AM
pulisher
10:15 AM

Eli Lilly and Co Stock (LLY) Moved Up by 6.15% on Jun 26: Drivers Behind the Movement - TradingKey

10:15 AM
pulisher
10:00 AM

U.S. Stocks Move | Eli Lilly and Co (LLY.US) Rises Over 4% as Jaypirca Marketing Authorization Application Submitted to European Commission - Moomoo

10:00 AM
pulisher
09:52 AM

Eli Lilly stock hits all-time high at 1183.0 USD - Investing.com

09:52 AM
pulisher
09:20 AM

Lilly’s Jaypirca receives positive EU regulatory opinion for CLL - Investing.com

09:20 AM
pulisher
08:09 AM

Eli Lilly (LLY) Receives Positive EMA Opinion for Jaypirca Treat - GuruFocus

08:09 AM
pulisher
07:59 AM

Flush with GLP-1 cash, Eli Lilly is on a Greater Boston shopping spree - NBC Boston

07:59 AM
pulisher
07:26 AM

Lilly’s Jaypirca receives positive EU regulatory opinion for CLL By Investing.com - Investing.com Canada

07:26 AM
pulisher
07:16 AM

Lilly's Jaypirca clears key EU hurdle for broader CLL use - Stock Titan

07:16 AM
pulisher
06:56 AM

Eli Lilly shares rise after EU panel backs expanded use of Jaypirca - Proactive financial news

06:56 AM
pulisher
04:23 AM

Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI - PR Newswire

04:23 AM
pulisher
04:11 AM

Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists - Insider Monkey

04:11 AM
pulisher
Jun 25, 2026

Nancy Pelosi Stock Tracker Flags Eli Lilly, Nokia After Trump Praise: ‘Keep An Eye On These Two’ - Yahoo Finance

Jun 25, 2026
pulisher
Jun 25, 2026

Obesity drugs approach a major milestone, and Lilly may have a 'game changer' ahead - CNBC

Jun 25, 2026
pulisher
Jun 25, 2026

LLY Maintained by Leerink Partners -- Price Target Raised to $12 - GuruFocus

Jun 25, 2026
pulisher
Jun 25, 2026

Six months in, Lilly says its supercomputer is starting to change the work with ‘near-infinite’ AI tokens - R&D World

Jun 25, 2026
pulisher
Jun 25, 2026

White House says Trump did not receive early access to new Lilly obesity drug - Indianapolis Business Journal

Jun 25, 2026
pulisher
Jun 25, 2026

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? - The Motley Fool

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly CEO announces Trump-backed Medicare program offering weight loss drugs for $50 a month - Fox Business

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly (LLY) Announces Medicare Coverage for Obesity Medicati - GuruFocus

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly CEO launches Medicare GLP-1 bridge program after working closely with Trump admin - Fox Business

Jun 25, 2026
pulisher
Jun 25, 2026

Lilly taps Abbisko for $1.9B discovery deal - BioWorld News

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly launches India's first RET-targeted therapy for solid tumours - Business Standard

Jun 25, 2026
pulisher
Jun 25, 2026

Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Benzinga

Jun 25, 2026
pulisher
Jun 25, 2026

5 Trending US Stocks to Buy Now - Insider Monkey

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly (LLY) Expands Medicare GLP-1 Coverage for Weight Management - GuruFocus

Jun 25, 2026
pulisher
Jun 25, 2026

Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,232 - 富途牛牛

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly launches cancer drug Tanstrive in India - The Economic Times

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly and Bayer support US trade probe into German drug prices - medwatch.com

Jun 25, 2026
pulisher
Jun 25, 2026

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management - PR Newswire

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly suspends access to drug discounts for some hospitals - reporter.net

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly & Co (NYSE:LLY) Screens as a Top Growth Stock with a Strong Technical Breakout Setup - ChartMill

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly’s dispensing and delivery service LillyDirect comes to UK - Chemist+Druggist

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly signs new partnership deal with China's Abbisko - medwatch.com

Jun 25, 2026
pulisher
Jun 25, 2026

FTAV’s further reading - Financial Times

Jun 25, 2026
pulisher
Jun 25, 2026

Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors - Insider Monkey

Jun 25, 2026
pulisher
Jun 24, 2026

Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration - Forbes

Jun 24, 2026
pulisher
Jun 24, 2026

Lilly’s GLP-1 windfall fuels M&A ‘land grab’ across 10 deals, $25B - BioWorld News

Jun 24, 2026
pulisher
Jun 24, 2026

Index Ventures entities exit Centessa (CNTA) stake as Eli Lilly acquisition closes - Stock Titan

Jun 24, 2026
pulisher
Jun 24, 2026

Centessa (CNTA) sale to Eli Lilly at $38 plus CVR detailed in Form 4 - Stock Titan

Jun 24, 2026
pulisher
Jun 24, 2026

Eli Lilly dives into hair loss treatments with investment in AI startup Absci - statnews.com

Jun 24, 2026
pulisher
Jun 24, 2026

Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI) - Seeking Alpha

Jun 24, 2026
pulisher
Jun 24, 2026

White House bats down speculation that Trump got access to Eli Lilly obesity drug - NewsNation

Jun 24, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
JNJ JNJ
$254.66
price up icon 3.99%
$253.35
price up icon 4.20%
MRK MRK
$128.66
price up icon 2.56%
NVS NVS
$155.41
price up icon 0.19%
AZN AZN
$188.41
price up icon 1.47%
Cap:     |  Volume (24h):